Citigroup’s ACELYRIN SLRN Stock Holding History

Citigroup’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-53,629	Closed	-$132K	–	5885
2025 Q1	$132K	Sell	53,629 -4,282	-7%	-$10.2K	﹤0.01%	4428
2024 Q4	$182K	Buy	57,911 +2,979	+5%	+$14.4K	﹤0.01%	4472
2024 Q3	$271K	Buy	54,932 +23,048	+72%	+$119K	﹤0.01%	4137
2024 Q2	$141K	Buy	31,884 +18,628	+141%	+$87.3K	﹤0.01%	4055
2024 Q1	$89.5K	Buy	13,256 +6,756	+104%	+$51.3K	﹤0.01%	4344
2023 Q4	$48.5K	Sell	6,500 -66,769	-91%	-$570K	﹤0.01%	4538
2023 Q3	$745K	Buy	+73,269	New	+$1.56M	﹤0.01%	2751

Other funds holding SLRN

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's SLRN Position: Q2 2025 in Review

Citigroup sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 53,629 shares — an estimated $132K sold.

Citigroup first reported a position in SLRN in Q3 2023 and held it in 7 quarters. The position peaked at $745K in Q3 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

Citigroup reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
Citigroup sold 53,629 ACELYRIN shares in Q2 2025, an estimated $132K.
Citigroup first reported a position in ACELYRIN in Q3 2023 and held it in 7 quarters.
Citigroup's ACELYRIN position peaked at $745K in Q3 2023.
2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.